Lung Deposition Using the Respimat Soft Mist™ Inhaler Mono and Fixed-Dose Combination Therapies: An / Analysis.

Tiotropium and olodaterol are mainstay treatments for chronic obstructive pulmonary disease (COPD) and yield important clinical improvements, especially when used in fixed-dose combination. Whilst previous studies have shown consistent delivery of tiotropium to the lungs with the Respimat inhaler, no such study has been carried out for olodaterol or the components of their fixed-dose combination (TIO/OLO). Combining and models, we measured the amount of drug retained in the mouth-throat area, entering the trachea and reaching the lung periphery. We applied a hybrid deposition model that considered the experimentally determined output of an Alberta throat model ( dose to lung) combined with a computational fluid dynamic model of the lungs (). Regardless of the COPD breathing pattern, ≥50% of the nominal dose of either tiotropium, olodaterol, or TIO and OLO in the fixed-dose combination reached the lung. Of the dose reaching the lungs, greater than 50% is deposited in the lung periphery (from generation 8 onwards). Our study demonstrated that aerosol delivery the Respimat inhaler achieved high deposition deep into the lung periphery with all formulations evaluated.